Saxenda (Liraglutide 3 mg) in Adolescents Ages 12 to 17: FDA Approval, Off-Label Use, and Clinical Evidence

What the FDA Actually Approved for This Age Group

The FDA extended Saxenda's approved indication to adolescents aged 12 to 17 on December 23, 2020, making liraglutide 3 mg the first GLP-1 receptor agonist approved for chronic weight management in this age group. [1] The approved population is narrow: adolescents must have a BMI at or above the 95th percentile for age and sex, which corresponds to the clinical definition of obesity in pediatrics. [2]

Prescribing outside these parameters, including in adolescents with BMI between the 85th and 94th percentile (overweight) or in children below age 12, is considered off-label use.

Why the Obesity-Only Threshold Matters

The FDA's approval boundary is not arbitrary. The key SCALE Teens trial (NCT02624791) enrolled only participants who met the obesity BMI cut-off, so the approved labeling reflects the studied population. [3] Extrapolating to overweight-only adolescents introduces uncertainty about both the benefit-to-risk ratio and the absolute weight-loss magnitude achievable at lower starting BMIs.

The American Academy of Pediatrics 2023 Clinical Practice Guideline on obesity treatment does support intensive behavioral and pharmacologic intervention for adolescents with obesity, listing GLP-1 agonists among the pharmacologic options. [4] That guideline does not endorse routine use in adolescents who are overweight but not obese.

Regulatory History at a Glance

Liraglutide 3 mg (Saxenda) first received FDA approval for adults with obesity or overweight plus at least one weight-related comorbidity in December 2014. [1] The six-year gap before the adolescent indication reflects the time required to design, execute, and analyze a dedicated pediatric trial under FDA Pediatric Research Equity Act requirements.

SCALE Teens: The Key Trial That Drove Approval

The SCALE Teens trial (NCT02624791) is the primary evidence base for liraglutide 3 mg in adolescents. Understanding its design and results is essential before discussing off-label applications. [3]

Trial Design

SCALE Teens was a 56-week, double-blind, placebo-controlled, randomized trial conducted across 39 sites in 13 countries. Investigators enrolled 251 adolescents aged 12 to 17 with obesity (BMI at or above 95th percentile). Participants were randomized 1:1 to liraglutide 3 mg or placebo, both combined with behavioral modification. [3]

The primary endpoint was change in BMI standard deviation score (SDS) from baseline to week 56.

Efficacy Results

Liraglutide 3 mg produced a mean BMI SDS reduction of 0.22 versus a 0.13 increase in the placebo group, a statistically significant difference (P<0.001). [3] Expressed as absolute BMI change, the liraglutide group lost 4.64 kg/m² compared with a gain of 1.06 kg/m² in the placebo group.

The New England Journal of Medicine published the full results in 2020. The authors reported that 43.3% of participants in the liraglutide group achieved at least a 5% reduction in BMI from baseline, compared with 18.7% in the placebo group. [3]

A key quote from that publication: "Liraglutide 3 mg, as compared with placebo, led to a significantly greater reduction in the BMI SDS in adolescents with obesity." [3]

Safety Profile in SCALE Teens

Gastrointestinal adverse events dominated the safety data. Nausea occurred in 62% of liraglutide-treated participants versus 27% on placebo. [3] Vomiting was reported in 42% versus 16%. Most events were mild-to-moderate and occurred during dose escalation.

Serious adverse events occurred in 9 participants on liraglutide and 1 on placebo, though none of the serious events in the liraglutide group were considered drug-related by the investigators. [3] Gallbladder-related events and increased heart rate are signals carried over from the adult literature and warrant monitoring in adolescents as well. [5]

Off-Label Use: Where It Actually Happens

Off-label prescribing of liraglutide 3 mg in adolescents covers three distinct scenarios: (1) age below 12, (2) overweight but not obese teens (BMI 85th, 94th percentile), and (3) use for indications other than weight management, such as type 1 diabetes or polycystic ovary syndrome (PCOS) in adolescents.

Adolescents Below Age 12

No randomized controlled trial data exist for liraglutide 3 mg in children under 12. [6] The FDA label explicitly restricts approval to ages 12 and above. Prescribing below this threshold is off-label and carries additional uncertainty about pharmacokinetics, developmental effects, and appropriate dosing.

One pharmacokinetic modeling study published in Clinical Pharmacokinetics suggested that exposure-response relationships for liraglutide in younger children may differ from adolescents due to differences in body composition and renal clearance, though this work did not study the 3 mg formulation specifically. [6] Clinicians considering this age group should involve a board-certified pediatric endocrinologist and document a thorough risk-benefit discussion.

Overweight Adolescents (BMI 85th, 94th Percentile)

This is arguably the most common off-label scenario. Some adolescents present with weight-related comorbidities (prediabetes, hypertension, dyslipidemia, non-alcoholic fatty liver disease) at BMI levels just below the obesity threshold. Clinicians occasionally ask whether liraglutide 3 mg is appropriate here. [7]

The adult Saxenda label allows prescribing for adults with BMI 27 to 29.9 kg/m² (overweight) if at least one weight-related comorbidity is present. [1] No equivalent provision exists in the pediatric label. Using this adult logic to justify off-label use in overweight adolescents is a clinical extrapolation, not a supported indication.

The Endocrine Society's 2017 Clinical Practice Guideline on pediatric obesity pharmacotherapy states that pharmacologic agents should generally be reserved for adolescents who have not responded to lifestyle intervention and who meet the obesity threshold. [8] This guideline predates the Saxenda adolescent approval but remains a commonly cited reference for threshold decisions.

PCOS and Insulin Resistance in Adolescent Girls

Polycystic ovary syndrome affects approximately 5 to 10% of adolescent girls and is frequently associated with insulin resistance and excess adiposity. [9] Some clinicians have explored GLP-1 receptor agonists, including liraglutide, to address both metabolic and reproductive features of PCOS in this age group.

A small randomized trial by Jensterle et al. (N=24, mean age 17.4 years) compared liraglutide 1.2 mg with metformin in adolescent girls with PCOS and obesity, reporting superior reductions in BMI and free androgen index with liraglutide over 12 weeks. [10] This study used a sub-maximal dose and a short duration. It does not establish a basis for routine off-label use, but it provides preliminary mechanistic rationale.

The American College of Obstetricians and Gynecologists (ACOG) does not currently recommend GLP-1 agonists as standard therapy for adolescent PCOS. [11]

Dosing Protocol in Adolescents

The approved dosing schedule for adolescents mirrors the adult titration: start at 0.6 mg subcutaneous once daily for one week, then increase by 0.6 mg increments each week until reaching the 3.0 mg maintenance dose. [1] The full escalation takes approximately five weeks.

Handling Dose Escalation in Practice

Adolescents, like adults, often experience the most significant gastrointestinal side effects during the escalation phase. Slowing the titration (for example, holding at 1.8 mg for two weeks before advancing) is commonly used in clinical practice to improve tolerability, though the FDA label does not formally endorse a modified schedule. If a dose is missed for more than three days, the label recommends restarting at 0.6 mg and re-escalating. [1]

Weight-Based Considerations

The approved labeling does not specify weight-based dosing for adolescents; the target dose is 3.0 mg regardless of body weight. [1] This is a meaningful distinction from some other pediatric medications and reflects the trial design, which used a fixed 3 mg target across all participants in SCALE Teens. [3]

Contraindications and Special Precautions in Adolescents

Contraindications in adolescents are identical to those in adults. Saxenda carries a black-box warning regarding thyroid C-cell tumors observed in rodent studies at clinically relevant exposures. [1] The drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). [1]

Monitoring Requirements

Adolescents on liraglutide 3 mg should be monitored for:

• Heart rate: liraglutide increases mean resting heart rate by approximately 2 to 3 beats per minute in adults; similar trends appeared in SCALE Teens. [3]
• Pancreatitis: acute pancreatitis has been reported with GLP-1 agonists; instruct patients and caregivers to discontinue the drug and seek care for persistent severe abdominal pain. [1]
• Gallbladder disease: rapid weight loss of any cause increases cholelithiasis risk; gallbladder ultrasound is warranted if symptoms develop. [5]
• Growth and pubertal development: long-term pediatric safety beyond 56 weeks is not established from trial data; [3] clinical judgment regarding monitoring of linear growth and Tanner staging is reasonable.
• Suicidal ideation: the FDA added a label warning for suicidal ideation across GLP-1 and GIP/GLP-1 products in 2023 following post-marketing reports, though causality remains unestablished. [12]

Thyroid Monitoring

Routine calcitonin monitoring is not recommended in the absence of symptoms, consistent with the adult Saxenda label. [1] Any neck mass, dysphagia, hoarseness, or dyspnea should prompt evaluation for medullary thyroid carcinoma.

How Saxenda Compares to Other Options in Adolescents

When Saxenda is not appropriate or not tolerated, clinicians working with adolescents aged 12 to 17 have a small but growing pharmacologic toolkit.

Orlistat

Orlistat 120 mg three times daily is FDA-approved for adolescents aged 12 and above. [13] Efficacy data show modest BMI reductions (roughly 0.5 to 1.0 kg/m² at 12 months in trials), substantially less than liraglutide 3 mg achieved in SCALE Teens. [13] Gastrointestinal side effects (oily spotting, fecal urgency, steatorrhea) make adherence difficult in adolescents.

Metformin

Metformin is not FDA-approved for obesity in adolescents, but it has a long off-label track record in this age group, particularly when insulin resistance or prediabetes is present. [14] A 2019 Cochrane review (Mead et al.) that included adolescent data found metformin produced small but statistically significant reductions in BMI (mean difference approximately 1.4 kg/m²) compared to placebo. [14] Metformin is not considered equivalent in weight-loss efficacy to liraglutide 3 mg.

Phentermine-Topiramate Extended Release

This combination product is not FDA-approved for adolescents below age 18. Off-label use exists, but the topiramate component carries teratogenicity and cognitive concerns that require careful discussion in adolescent girls of reproductive age. [15]

Semaglutide (Wegovy)

Wegovy (semaglutide 2.4 mg weekly) received FDA approval for adolescents aged 12 and above with obesity in December 2022, two years after Saxenda's adolescent approval. [16] The STEP Teens trial (N=201) demonstrated a mean BMI reduction of 16.1% versus 0.6% with placebo at 68 weeks, [16] substantially larger than what SCALE Teens reported for liraglutide. Most treatment guidelines and clinical commentary now favor semaglutide over liraglutide in adolescents given the superior efficacy data, though head-to-head trials in adolescents do not exist.

Practical Prescribing Considerations for Clinicians

Off-label use of Saxenda in adolescents requires a structured approach. The following points reflect both the approved labeling and standard clinical practice conventions.

Informed Consent and Documentation

Any off-label use requires explicit informed consent from both the adolescent (assent, where developmentally appropriate) and a legal guardian. [17] Documentation should include: (1) the rationale for off-label use, (2) the specific indication and why approved alternatives were considered insufficient, (3) the known evidence base, and (4) the monitoring plan. The FDA's off-label use guidance for practitioners clarifies that physicians may prescribe approved drugs outside their labeled indications when supported by sound medical evidence. [17]

Multidisciplinary Team

The American Academy of Pediatrics 2023 guideline recommends that pharmacotherapy for adolescent obesity be delivered within the context of intensive health behavior and lifestyle treatment, not as monotherapy. [4] A team including a registered dietitian, behavioral health specialist, and pediatric endocrinologist or obesity medicine specialist represents best practice.

Duration of Treatment

SCALE Teens ran for 56 weeks. Post-trial data from the adult literature show that discontinuation of liraglutide leads to substantial weight regain; [18] the same pattern is expected in adolescents. Clinicians should discuss the likelihood of long-term or indefinite therapy at the time of prescribing, and ensure that payer coverage, cost, and the patient's developmental trajectory are all factored into the treatment plan.

A 2022 post-hoc analysis of the SCALE Teens extension (NCT02956447, N=125) found that participants who transitioned off liraglutide regained most of the lost BMI within 26 weeks of discontinuation, with mean BMI SDS returning toward baseline levels. [19] This trajectory mirrors what is seen in adult trials and reinforces that obesity is a chronic condition requiring ongoing treatment consideration.

Reimbursement and Access Barriers in Adolescents

Insurance coverage for Saxenda in adolescents is inconsistent. As of 2024, many commercial plans require documented prior authorization, demonstration of BMI at or above the 95th percentile, and evidence of prior lifestyle intervention failure. Medicaid coverage varies substantially by state.

The list price for Saxenda is approximately $1,400 per month without insurance. Novo Nordisk maintains a patient assistance program for eligible patients. Clinicians should verify formulary status before initiating treatment and prepare for prior authorization requirements that may require submission of growth charts, comorbidity documentation, and behavioral treatment records. [20]